Wegovy produces more weight loss than Ozempic for a straightforward reason: it delivers a higher dose of the same drug. Both contain semaglutide, a once-weekly injection that mimics a gut hormone involved in appetite and blood sugar regulation. Ozempic tops out at 2 mg per week and is approved for type 2 diabetes, while Wegovy reaches 2.4 mg and is approved specifically for weight management. That dosing gap, combined with differences in who gets prescribed which product, accounts for virtually all of the gap in real-world results.
Same Molecule, Different Packaging
Semaglutide was developed first as a diabetes treatment. It went through clinical trials under the brand name Ozempic with weekly doses of 0.5 mg, 1 mg, and eventually 2 mg, aimed at lowering blood sugar in people with type 2 diabetes. Weight loss was a consistent and pronounced side effect in those trials, so the manufacturer ran a separate program testing a higher 2.4 mg dose explicitly for weight reduction in people with or without diabetes. That program became Wegovy.
The practical consequence is that when someone takes Ozempic for weight loss, they are almost always using it off-label and receiving a lower maximum dose than what the weight-loss trials actually tested. A letter in JAMA Internal Medicine made this point directly: studies comparing semaglutide to other medications without accounting for dosage can be misleading, because Ozempic users getting the diabetes-labeled formulation are likely excluded from the 2.4 mg regimen that the weight-loss evidence is built on.1JAMA Network. Semaglutide vs Tirzepatide Dosages for Weight Loss So when you see someone say “Ozempic didn’t work as well for me,” the dose they were on matters enormously.
How Much Weight Semaglutide at 2.4 mg Actually Produces
The landmark trial for Wegovy’s approval, known as STEP 1, enrolled adults with overweight or obesity who did not have type 2 diabetes. At 68 weeks, people taking semaglutide 2.4 mg lost an average of about 15% of their body weight, compared to roughly 2.4% with placebo.2PubMed. Once-Weekly Semaglutide in Adults with Overweight or Obesity For a person starting at 220 pounds, that works out to losing about 33 pounds over roughly 16 months.
The results were consistent across subsequent trials. A review of the STEP program found that semaglutide 2.4 mg was associated with average losses of about 15% to 17% from baseline to week 68, with roughly two-thirds to four-fifths of participants losing at least 10% of their body weight.3PubMed Central. Semaglutide for the treatment of overweight and obesity: A review A longer trial, STEP 5, showed that the weight loss held up at two years, with an average reduction of about 15% at week 104.4Nature Medicine. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
These numbers represent the 2.4 mg Wegovy dose. Ozempic’s maximum approved dose of 2 mg for diabetes has never been tested head-to-head for weight loss in a large clinical trial, and the lower doses of 0.5 mg and 1 mg produce proportionally less weight reduction. If your doctor prescribes Ozempic off-label at 1 mg for weight management, expecting 15% loss is unrealistic based on the evidence.
Why People With Diabetes Lose Less Weight on Semaglutide
One of the clearest patterns in the data is that people with type 2 diabetes lose significantly less weight on semaglutide than people without it. A real-world study found that patients without diabetes lost about 12% of their body weight at six months, while those with diabetes lost about 7%.5JAMA Network Open. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity A separate study looking at one-year outcomes confirmed the pattern: people prescribed semaglutide for obesity lost about 6% on average, while those prescribed it for diabetes lost about 3%.6JAMA Network Open. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
This matters for the Ozempic versus Wegovy question because most Ozempic users have type 2 diabetes, which itself dampens the weight-loss response, while most Wegovy users do not. A study tracking semaglutide outcomes by diabetes severity found that people with more severe metabolic disease lost less weight at every time point, with those in the mildest category losing roughly 9% of their body weight at 12 months and those in the most severe category losing about 5%.7eClinicalMedicine. Weight loss outcomes of semaglutide based on individualized metabolic surgery score in patients with type 2 diabetes: a multicentered cohort study The reasons likely involve insulin resistance, medications that promote weight gain, and differences in how the body handles energy when blood sugar regulation is impaired.
How the Drug Works
Semaglutide mimics a hormone called GLP-1 that your gut releases after eating. In the brain, it acts on regions that regulate appetite and reward, reducing hunger and making you feel satisfied sooner. Peripherally, it slows stomach emptying and improves blood sugar control by boosting insulin release and dialing back glucagon.8PubMed. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation GLP-1 receptors are spread across the nervous system, including the gut’s own nerve network, which is why the drug has such broad effects on digestion and appetite.9PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery
Many people describe a phenomenon called “food noise” quieting down on semaglutide: the constant background hum of food-related thoughts fades. Neuroimaging and behavioral data suggest the drug influences brain circuits involved in cue salience and reward anticipation, though researchers are still pinning down the causal chain.10PubMed Central. Quieting “Food Noise”: How GLP-1s and Mindfulness Rewire the Default Mode Network (DMN) and Reward Circuits This effect can be profoundly helpful, but it also means that when people stop the medication, those food-related thought patterns can return.
Side Effects Are Dose-Dependent but Generally Manageable
Because Ozempic and Wegovy contain the same molecule, their side-effect profiles are essentially identical in character, though higher doses tend to produce more frequent gastrointestinal complaints. Nausea, vomiting, diarrhea, and constipation are the most common, and they are typically dose-dependent and transient, meaning they often improve as the body adjusts over several weeks.11PubMed Central. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations This is why both drugs use a gradual dose-escalation schedule: you start low and step up over weeks to minimize nausea.
One rarer concern worth knowing about is gastroparesis, where the stomach’s ability to move food along becomes severely impaired. Because semaglutide slows gastric emptying by design, rapid dose escalation or use in people already prone to motility problems can sometimes tip the balance too far.12PubMed Central. Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient If you develop persistent vomiting or severe bloating, that warrants a conversation with your prescriber rather than pushing through it.
Cardiovascular Benefits Go Beyond the Scale
For the question of which is “better,” weight loss is not the only dimension that matters. The SELECT trial, one of the largest cardiovascular outcome studies ever done with a weight-loss drug, tested semaglutide 2.4 mg (the Wegovy dose) in people with obesity and established heart disease but without diabetes. Over a median follow-up of about three years, major cardiovascular events like heart attack, stroke, and cardiovascular death occurred in about 6.5% of people on semaglutide versus 8% on placebo, a 20% relative risk reduction.13PubMed. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
An exploratory analysis of the same trial found that semaglutide also reduced hospital admissions across a range of categories, including cardiac events, infections, and respiratory causes.14JAMA Cardiology. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial No equivalent cardiovascular outcomes trial has been run with Ozempic’s lower doses in a non-diabetic population. So while both brands reduce heart risk factors like blood sugar and inflammation, the hard evidence for preventing heart attacks and strokes specifically belongs to the 2.4 mg Wegovy dose.
What Happens When You Stop
Weight regain after stopping semaglutide is real and substantial. The STEP 1 trial extension followed participants after they stopped treatment: by one year off the drug, people had regained about two-thirds of the weight they had lost. Net weight loss from the study’s start to one year post-treatment was about 5.6%, down from the roughly 15% lost while on the drug. Most of the cardiometabolic improvements seen during treatment also drifted back toward baseline.15PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Real-world data paints a more varied picture. One study of people discontinuing semaglutide or tirzepatide found that average weight change from discontinuation to one year later was relatively modest: about 0.5% regain for those treated for obesity and actually a slight further loss for those treated for diabetes. But the averages masked wide individual variation.16PubMed Central. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide Some people maintained their loss, others regained substantially. The difference may come down to whether people switched to another medication, had weight-loss surgery, or made lasting behavioral changes during treatment. The bottom line is that for most people, semaglutide works best as a long-term medication rather than a short-term fix.
Real-World Persistence Is the Biggest Obstacle
The best drug in the world does not help if people stop taking it, and dropout rates with GLP-1 medications are high. Among commercially insured adults without diabetes, overall GLP-1 persistence was only about 32% at one year. Ozempic had the best persistence of the options studied, at about 47% at one year, which sounds reasonable until you realize that means more than half of the people who started it had stopped within 12 months.17PubMed Central. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes
The gap between trial results and real-world results reflects this directly. In a cohort study within an integrated health system, the 44% of patients who stayed on semaglutide for a full year lost an average of about 14% of their body weight, which is close to what the clinical trials show. The remaining 56% who dropped off early lost only about 6%.18PubMed Central. Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system Cost is a major factor: Wegovy’s list price exceeds $1,300 per month without insurance, and coverage varies wildly by plan and employer. Ozempic is sometimes easier to get covered through a diabetes indication, which is part of why off-label use became so common.
What Semaglutide Does to Body Composition
A persistent concern with rapid weight loss of any kind is losing muscle along with fat. A study tracking body composition in people on semaglutide found that total fat mass dropped by about 19% over 12 months, while lean mass dropped by about 3 kg in the first seven months and then stabilized. The proportion of lean mass relative to total body mass actually increased, meaning people became proportionally leaner even though they lost some absolute muscle.19PubMed Central. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study
Interestingly, a preprint comparing semaglutide to tirzepatide found that a “depletive” pattern of losing more than 20% of body weight along with more than 5% lean body mass was significantly more common with tirzepatide than semaglutide during the first year of therapy. A more favorable pattern of losing over 10% of body weight while preserving lean mass was slightly more common with semaglutide, though the difference was not statistically significant.20medRxiv. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping Resistance training during treatment remains the best-supported strategy for preserving muscle, regardless of which medication you are on.
How Tirzepatide Changes the Conversation
The comparison between Ozempic and Wegovy is increasingly being overtaken by a different question: how does semaglutide compare to tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss)? Tirzepatide acts on two hormone receptors instead of one, and the weight-loss results are consistently larger. A meta-analysis of clinical trials and real-world data found that tirzepatide produced about 4 kg more weight loss than semaglutide overall, with the gap widening at higher doses.21PubMed Central. Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data
Network meta-analyses that pool data from randomized trials back this up. Tirzepatide at its higher doses (10 mg and 15 mg) was associated with roughly 5% to 6% greater weight reduction and about 5 cm more waist circumference loss compared to semaglutide 2.4 mg.22PubMed Central. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials Tirzepatide ranked highest for both weight reduction and waist circumference reduction across multiple analyses.23PubMed. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis However, tirzepatide does not yet have a completed cardiovascular outcomes trial in people without diabetes, so semaglutide still holds a unique evidence advantage for heart protection.
The Compounded Semaglutide Gamble
Because of high costs and drug shortages, compounded versions of semaglutide have become widely available from compounding pharmacies. These are not FDA-approved products, and the safety signal is concerning. An analysis of FDA adverse event reports found that compounded GLP-1 formulations had significantly higher reporting odds for abdominal pain, nausea, diarrhea, and, more alarmingly, suicidal ideation and gallbladder inflammation compared to the branded products. Compounded products also showed dramatically higher odds of preparation errors, contamination issues, and compounding or manufacturing problems. Hospitalization odds were more than twice as high for compounded products.24PubMed. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
The regulatory situation with compounded semaglutide remains fluid. While there is a general recommendation against using non-FDA-approved compounded versions, some clinicians do prescribe them when patients cannot access or afford the branded products, weighing potential harms against the health consequences of untreated severe obesity.25JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. Legal, safety, and practical considerations of compounded injectable semaglutide If you are considering a compounded product, the quality and oversight of the specific compounding pharmacy matters enormously. Not all compounders carry the same risk, but you generally have no way to verify potency or sterility yourself.
How Semaglutide Compares to Bariatric Surgery
For people with severe obesity, the relevant comparison is often not Ozempic versus Wegovy but semaglutide versus surgery. Bariatric procedures like gastric bypass and sleeve gastrectomy still produce greater total weight loss and higher rates of diabetes remission than any medication currently available. The trade-off is surgical risk, recovery time, and irreversibility. A comparative review found that while bariatric surgery showed superior overall efficacy in weight reduction and diabetes management, semaglutide offered a noninvasive alternative with meaningful weight loss and fewer adverse events.26PubMed Central. What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue In practice, these options are increasingly used together rather than as either-or choices, with some patients starting medication before surgery or using it afterward to prevent regain.
Semaglutide’s Effects on Gut Bacteria
An emerging area of research is what happens to the gut microbiome during semaglutide treatment. A study of patients with type 2 diabetes found that semaglutide treatment led to significant reductions in body weight, blood sugar, and blood lipids, with accompanying shifts in gut bacterial populations.27Diabetes, Metabolic Syndrome and Obesity. The Effect of Semaglutide on Gut Microbiota in Chinese Patients with Type 2 Diabetes Poorly Controlled by Metformin Whether these microbiome changes are a direct drug effect or simply a consequence of eating differently and losing weight is still an open question. It is possible that some of semaglutide’s metabolic benefits are partly mediated through the gut ecosystem, but the evidence is too early to draw firm conclusions. This is the kind of question that will likely take years of careful study to untangle, and anyone claiming definitive answers about probiotics or gut health supplements to “enhance” your GLP-1 response is ahead of the science.